Response to dissociative identity disorder letters from martínez-taboas et Al. And brand et Al.

08:00 EDT 1st April 2013 | BioPortfolio

Summary of "Response to dissociative identity disorder letters from martínez-taboas et Al. And brand et Al."

No Summary Available


Department of Psychiatry McGill University Montreal, Quebec, Canada.

Journal Details

This article was published in the following journal.

Name: The Journal of nervous and mental disease
ISSN: 1539-736X
Pages: 356-7


PubMed Articles [18174 Associated PubMed Articles listed on BioPortfolio]

Childhood Traumatic Experiences, Dissociative Symptoms and Dissociative Disorder Comorbidity among Patients with Panic Disorder: A Preliminary Study.

This study assesses childhood trauma history, dissociative symptoms, and dissociative disorders comorbidity in patients with Panic Disorder (PD). Ninety two psychotropic drug-naive patients with PD, r...

Psychopharmacologic treatment of dissociative fugue and PTSD in an ethiopian refugee.

Despite widespread awareness of their frequent co-occurrence, little is known about treatment of individuals with comorbid posttraumatic stress disorder (PTSD) and dissociative disorders. Patients wit...

Fighting the Whole System: Dissociative Identity Disorder, Labelling Theory and Iatrogenic Doubting.

This research examines how individuals diagnosed with Dissociative Identity Disorder (DID) construe their experiences of being labelled with a contested diagnosis. Semi-structured interviews were cond...

Distinguishing simulated from genuine dissociative identity disorder on the MMPI-2.

Due to high elevations on validity and clinical scales on personality and forensic measures, it is challenging to determine if individuals presenting with symptoms of dissociative identity disorder (D...

Dissociative amnesia.

Dissociative amnesia is one of the most enigmatic and controversial psychiatric disorders. In the past two decades, interest in the understanding of its pathophysiology has surged. In this report, we ...

Clinical Trials [3677 Associated Clinical Trials listed on BioPortfolio]

Stabilizing Group Treatment of Complex Trauma: A Randomized Controlled Trial

The research project outlined in this proposal aims to investigate the effectiveness of stabilizing group treatment as an add-on to conventional treatment, for patients with Post Traumatic...

Point Of Care Testing In Danish General Practice

The aim of this project is to evaluate the efficacy of electronic reminder letters versus postal reminder letters on general practices adherence to clinical quality guidelines regarding Po...

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Background: - MART-1 is a gene present in melanoma cells. - An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a ty...

Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder

Our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.

Naltrexone in Borderline Personality Disorder

The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.

Medical and Biotech [MESH] Definitions

A dissociative disorder in which the individual adopts two or more distinct personalities. Each personality is a fully integrated and complex unit with memories, behavior patterns and social friendships. Transition from one personality to another is sudden.

A class of traumatic stress disorders that is characterized by the significant dissociative states seen immediately after overwhelming trauma. By definition it cannot last longer than 1 month, if it persists, a diagnosis of post-traumatic stress disorder (STRESS DISORDERS, POST-TRAUMATIC) is more appropriate.

Sudden temporary alterations in the normally integrative functions of consciousness.

The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.